Management has concluded that Life Sciences, Mobile Solutions, and Power Solutions constitute our operating segments. Life Sciences, Mobile Solutions, and Power Solutions are considered operating segments as each engages in business activities for which it earns revenues and incurs expenses, discrete financial information is available for each, and this is the level at which the Chief Operating Decision Maker (“CODM”) reviews discrete financial information for purposes of allocating resources and assessing performance.

Life Sciences

Life Sciences is focused on growth in the medical end market, primarily in the orthopaedics and medical/surgical end markets. Within this group we combine advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies, and finished devices. We manufacture a variety of components, assemblies, and instruments, such as surgical knives, bioresorbable implants, surgical staples, cases and trays, orthopaedic implants and tools, laparoscopic devices, and drug delivery devices for the orthopaedics and medical/surgical end markets.

Mobile Solutions

Mobile Solutions is focused on growth in the general industrial and automotive end markets. We have developed an expertise in manufacturing highly complex, system critical components for fuel systems, engines and transmissions, power steering systems, and electromechanical motors on a high-volume basis. This expertise has been gained through investment in technical capabilities, processes and systems, and skilled program management and product launch capabilities.

Power Solutions

Power Solutions is focused on growth in the electrical and aerospace and defense end markets. Within this group we combine materials science expertise with advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies, and finished devices used in applications ranging from power control to flight control and for military devices. We manufacture a variety of products including electrical contacts, connectors, contact assemblies, and precision stampings for the electrical end market and high precision products for the aerospace and defense end markets utilizing our extensive process technologies for optical grade plastics, thermally conductive plastics, titanium, Inconel, magnesium, and electroplating.

Segment Results

The following tables present certain operations information by reportable segment.



	Life Sciences		Mobile Solutions		Power Solutions		Corporate and Consolidations				Total
Year Ended December 31, 2019
Net sales	$	359,732	$	297,749	$	192,100	$	(2,130	)	(a)	$	847,451
Depreciation and amortization	46,905		27,146		15,301		2,494				91,846
Income (loss) from operations	28,157		9,553		13,881		(41,702		)		$	9,889
Interest expense											(57,155		)
Other											(4,433		)
Loss before provision for income taxes and share of net income from joint venture											$	(51,699	)
Share of net income from joint venture	$	—	$	1,681	$	—	$	—			$	1,681
Expenditures for long-lived assets	21,445		24,969		4,457		3,132				54,003
Total assets	811,526		373,256		310,545		46,657			(b)	1,541,984



	Life Sciences		Mobile Solutions			Power Solutions			Corporate and Consolidations				Total
Year Ended December 31, 2018
Net sales	$	248,173	$	335,037		$	189,778		$	(2,331	)	(a)	$	770,657
Depreciation and amortization	28,091		26,217			14,753			2,067				71,128
Goodwill impairment	—		73,442			109,100			—				182,542
Income (loss) from operations	19,136		(55,079		)	(95,115		)	(48,806		)		$	(179,864	)
Interest expense													(61,243		)
Other													(20,903		)
Loss before benefit for income taxes and share of net income from joint venture													$	(262,010	)
Share of net income from joint venture	$	—	$	(14,390	)	$	—		$	—			$	(14,390	)
Expenditures for long-lived assets	14,645		36,660			6,459			6,272				64,036
Total assets	802,770		354,542			297,947			45,643			(b)	1,500,902



	Life Sciences		Mobile Solutions		Power Solutions		Corporate and Consolidations				Total
Year Ended December 31, 2017
Net sales	$	98,329	$	336,852	$	186,602	$	(1,990	)	(a)	$	619,793
Depreciation and amortization	12,088		24,491		14,657		1,170				52,406
Income (loss) from operations	13,271		33,071		23,440		(38,002		)		$	31,780
Interest expense											(52,085		)
Other											(39,902		)
Loss before benefit for income taxes and share of net income from joint venture											$	(60,207	)
Share of net income from joint venture	$	—	$	5,211	$	—	$	—			$	5,211
Expenditures for long-lived assets	—		24,056		5,443		6,907				36,406
Total assets	353,208		427,027		385,558		307,916				1,473,709

_______________________________

(a) Includes eliminations of intersegment transactions which occur during the ordinary course of business.

(b) Total assets in Mobile Solutions includes $21.8 million and $20.4 million as of December 31, 2019 and 2018, respectively, related to the investment in our 49% owned joint venture (Note 11).

The following table summarizes the net sales and income (loss) from operations from acquisitions in the Life Sciences and Power Solutions groups for the years ended December 31, 2018 and 2017.



	Year Ended December 31,
	2018		2017
Net sales
Paragon Medical	$	116,998	$	—
Other	42,636		6,682

Income (loss) from operations
Paragon Medical	$	8,086	$	—
Other	1,816		(458		)

The following table summarizes long-lived tangible assets by geographical region.



	Property, Plant, and Equipment, Net As of December 31,
	2019		2018
United States	$	250,163	$	235,975
Europe	54,829		50,143
Asia	43,128		42,657
Mexico	1,388		7,647
S. America	25,005		24,606
All foreign countries	$	124,350	$	125,053
Total	$	374,513	$	361,028